Gastric bypass surgery leads to profound changes in the secretion of gut hormones with
effects on metabolism, appetite, and food intake. Here, we discuss their contributions to the …

Improvements in both liquid chromatography (LC) and mass spectrometry (MS)
instrumentation have greatly enhanced proteomic and small molecule metabolomic analysis …

Background Weight loss is often key in the management of obese or overweight patients
with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight …

Results: In study 1, food intake decreased by 35% following RYGB compared with before
surgery. Before surgery, GLP-1 receptor blockage increased food intake but no effect was …

Obesity and Type 2 diabetes represent global health challenges, and there is an unmet
need for long-lasting and effective pharmacotherapies. Although long-acting glucagon-like …

The proglucagon-derived peptide hormone, glucagon, comprises 29 amino acids. Its
secretion from the pancreatic α cells is regulated by several factors. Glucagon increases …

Background: Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective
treatment of obesity, although limited by availability and operative risk. The gut hormones …

Objective To determine changes in incretins, systemic inflammation, intestinal permeability
and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with …

25 years ago, the future of treating obesity and diabetes focused on end organs known to be
involved in energy balance and glucose regulation, including the brain, muscle, adipose …

Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released
from the endocrine L-cells of the gut after enzymatic processing by the precursor …